Recent Articles in News & Analysis

Shanghai Sanyou Bio, a biologics CRO, will integrate a proprietary generative AI antibody design platform (GeoBiologics) developed by BioGeometry, a Beijing AI company. Sanyou has developed an antibody library construction platform, based on nine super-trillion antibody libraries as its core, with a capacity of up to 10 trillion. BioGeometry specializes in AI-driven protein design with an R&D platform. The combination will offer a Dry-Wet antibody R&D platform that integrates BioGeometry's AI algorithm with Sanyou Bio's wet lab capabilities. Sanyou expects the AI platform to speed up development and add new targets for candidates. More details....

Share this with colleagues:  

South Korea’s Genexine will merge with EPD Biotherapeutics, a company developing an innovative targeted protein degradation (TPD) in exchange for 16% of Genexine’s stock, worth about $180 million. EPD has developed a bioPROTAC platform, known as EPDegTM, that is based on an mRNA-based bioPROTAC technology. The platform creates fusion-protein degraders delivered as mRNA-LNP that do not depend on tissue specific expression of E3 ligase. EPD believes the technology will overcome the limitations of existing small molecule-based PROTAC technology. More details....

Stock Symbol: (KOSDAQ: 095700)

Share this with colleagues:  

Zhiyi Biotech of Guangzhou, a company developing live biotherapeutic products (LBPs), reported its heat-killed Bacteroides fragilis product for Chemotherapy-induced Diarrhea (CID) was well-tolerated in a US trial. The clinical study was a randomized, double-blind, placebo-controlled, sequential dose-escalation trial that examined the safety and tolerability of SK10 in 24 healthy adult subjects. All dose levels of SK10 were generally safe and well tolerated. Based on the results, Zhiyi will advance SK10 into a trial that tests the candidate in CID patients. Zhiyi’s lead product, SK08, is in a Phase III clinical trial to treat IBS-D, which puts it ahead of the other LBPs in China. More details....

Share this with colleagues:  

Chengdu Hinova Pharma received US FDA Fast Track designation for HP518, an investigational drug for Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC). HP518 is a potent PROTAC AR degrader that has shown efficacy in AR+ TNBC. According to Hinova, the molecular subforms of TNBC are particularly aggressive forms of breast cancer, without targeted treatment options but accounting for approximately 15-20% of all breast cancer cases. They lack estrogen and progesterone receptors along with HER2 expression. However, up to 50% of TNBC cases express the androgen receptor, HP518’s potential target. More details....

Stock Symbol: (SHA: 688302)

Share this with colleagues:  

AusperBio, a Hangzhou-Boston biotech, reported its lead drug, an unconjugated antisense oligonucleotide (ASO) that targets all HBV mRNA, has now treated 193 participants in global and China clinical trials. The patient base includes 101 participants with chronic HBV. AHB-137 is designed to trigger the degradation of all HBV RN. The candidate is a novel unconjugated antisense oligonucleotide (ASO) with a dual mechanism the could become a backbone for novel therapies that aim to find a functional cure for CHB. The novel ASO is currently in a global Phase Ib trial and a Phase II trial in China. More details....

Share this with colleagues: